Generate Biomedicines Debuts with 6% Price Increase
Generate Biomedicines made its public debut last week. The clinical‑stage company, which positions itself as a pioneer in AI‑driven drug design and development, enters the market with a pitch that its generative biology platform can accelerate and broaden therapeutic discovery.LATEST IPOS AND DIRECT LISTINGS:Generate Biomedicinesopened on February 27 at $15.00. The company priced 25M shares at $16.00. The deal priced at the midpoint of the $15.00-$17.00 target range. Generate Biomedicines is a clinical-stage generative biology company that says it is "pioneering the AI revolution in biotechnology and drug design and development."RECENT SPAC IPOS:Fortress Value Acquisition Vopened on February 26 at $10, after it priced its initial public offering of 25M Class A ordinary shares at a price of $10.00 per share.APEX Tech Acquisitionopened on February 26 at $9.98, after it priced its initial public offering of 10M units at an offering price of $10.00 per unit, with each unit consisting of one ordinary share and one right to receive one-fourth of one ordinary share upon the consummation of an initial business combination.MOZAYYX Acquisitionopened on February 25 at $9.96, after it priced its upsized initial public offering of 26.1M units at $10.00 per unit.ClearThink 1 Acquisitionopened on February 24 at $9.95, after it priced its initial public offering of 12.5M units at $10.00 per unit.PERFORMANCE:Price as of 11:00 am ET on Monday, March 2 -Generate Biomedicines – up over 6% at $13.48.RECENT IPOS TO WATCH:Forgent Power Solutions, Eikon Therapeutics, Bob's Discount Furniture, and Veradermicsare already seeing coverage roll out, while SpyGlass Pharma, Agomaband Once Upon A Farmare among stocks that could see new coverage this week as the quiet periods for banks that underwrote the companies' IPOs expire.UPCOMING IPOS:Upcoming IPO and direct listings expected include Liftoff, Cerebras Systems, ayPay, and OpenAI.Clickto see upcoming IPO calendar on TipRanks.Liftoff Mobile- The company announced that it has confidentially submitted a draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The total number of shares to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market and other conditions and the completion of the SEC's review process.Cerebras Systems– The company has filed confidentially for a U.S. initial public offering, The Information's Valida Pau and Katie Roof. The re-filing comes after a major sales pact with OpenAI, the authors note.PayPay Corporation- The company filed for an initial public offering of American depositary shares, or ADSs, and has applied to list the ADSs on the Nasdaq Global Select Market under the symbol "PAYP." The prospects filed with the SEC states, "As Japan's leading financial technology company, we are dedicated to our goal of becoming a digital finance platform for all... We launched this service in October 2018 and it rapidly expanded to become a nation-wide leading cashless payments ecosystem that had approximately 72 million PayPay registered users as of December 31, 2025, representing a penetration of 75% among 96 million smartphone users in Japan. With the acquisition of PayPay Card Corporation in October 2022, our platform evolved to a next-generation payments ecosystem, seamlessly integrating our code-based payment and credit card payment services through our PayPay app."OpenAI- The company is accelerating its plans for a public listing as rivalry with Anthropic intensifies, now planning on listing in Q4 of this year, Berber Jin, Corrie Driebusch, and Kate Clark of The Wall Street Journal. OpenAI is holding discussions with Wall Street banks about a potential initial public offering and has hired several executives to oversee its finance team, sources told the Journal.SpaceX- Elon Musk is targeting mid-June for the timing of SpaceX's initial public offering, IPO, Ivan Levingston, Stephen Morris, and Mercedes Ruehl of The Financial Times, citing five people familiar with the matter. The company is looking to raise $50B at a valuation of $1.5T, the sources added.Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.
Trade with 70% Backtested Accuracy
Analyst Views on GENB
About GENB
About the author
HarbourVest Partners Acquires Stake in Generate Biomedicines
- New Investment Disclosure: HarbourVest Partners disclosed a new position in Generate Biomedicines (GENB) by acquiring 1,722,210 shares in Q1 2026, with an estimated transaction value of $21.03 million, indicating strong conviction in the company's future.
- Position Value Analysis: As of March 31, 2026, the value of Generate Biomedicines' position was $21.53 million, representing 21% of HarbourVest's reportable AUM, highlighting the significance of this investment in their portfolio.
- Financial Overview: Generate Biomedicines has a market capitalization of $2 billion, and despite a revenue decline to $7.2 million year-over-year, the company holds $516.6 million in cash and equivalents, providing a runway into the first half of 2028.
- Clinical Progress and Strategy: The lead candidate GB-0895 is advancing through Phase 3 trials, with management emphasizing progress across multiple programs, showcasing the company's potential in drug development and AI-driven discovery platforms.
HarbourVest Acquires 1.72 Million Shares of Generate Biomedicines
- Share Acquisition: HarbourVest initiated a position in Generate Biomedicines by acquiring 1,722,210 shares in Q1 2026, with an estimated transaction value of $21.03 million, indicating strong conviction in the company's potential, especially given its clinical pipeline advancements.
- Asset Growth: As of March 31, 2026, HarbourVest's position in Generate was valued at $21.53 million, reflecting a 21% increase in reportable assets under management, driven by both share purchases and favorable price movements in the market.
- Financial Position: Generate Biomedicines ended the quarter with $516.6 million in cash and equivalents, despite a revenue decline from $8.8 million to $7.2 million year-over-year, as the company ramps up investments in late-stage clinical programs, showcasing its long-term growth potential.
- Clinical Progress: The lead candidate GB-0895 is advancing through Phase 3 trials for severe asthma, while oncology candidates are expected to initiate key clinical activities later this year, highlighting the company's ongoing commitment to drug development and strategic positioning in the biotech sector.
Generate Biomedicines to Participate in Goldman Sachs Global Healthcare Conference
- Conference Participation Announcement: Generate Biomedicines (NASDAQ:GENB) has announced its participation in the Goldman Sachs Global Healthcare Conference on June 8, 2026, with a live webcast expected to enhance visibility and trust among investors.
- Innovative Platform Overview: The company focuses on the intersection of machine learning, biological engineering, and medicine, aiming to accelerate drug development through its generative platform to create superior therapeutic solutions that meet urgent patient needs.
- Pipeline Expansion: By integrating computational design with large-scale biological experimentation, the platform has successfully generated a variety of therapeutic solutions targeting health challenges that traditional methods struggle to address, showcasing significant innovation potential and market competitiveness.
- Company Background Summary: Founded in 2018, Generate Biomedicines is leading a fundamental shift from drug discovery to drug generation, committed to developing novel therapies for hard-to-drug targets, thereby advancing the progress and development of the biopharmaceutical industry.
Generate Biomedicines Reports Q1 2026 Financial Results and Clinical Progress
- Improved Financial Position: As of March 31, 2026, Generate reported cash and cash equivalents of $516.6 million, a significant increase from $221.5 million on December 31, 2025, reflecting the successful completion of its IPO which raised $369.3 million in net proceeds, thereby securing funding for future operations.
- Increased R&D Expenses: Research and development expenses for Q1 2026 reached $57.8 million, up from $46.8 million in Q1 2025, primarily driven by continued investment in the GB-0895 program, indicating a strategic focus on severe asthma treatment.
- Significant Clinical Progress: Generate is advancing its GB-0895 program into Phase 3 clinical trials for severe asthma and is conducting a Phase 1b trial for COPD, which is expected to enhance the company's competitive position in the respiratory disease market.
- Widening Net Loss: The net loss for Q1 2026 was $61.7 million, compared to $44.3 million in Q1 2025, largely due to increased stock-based compensation expenses, which may negatively impact investor confidence.
Generate Biomedicines Reports Q1 Highlights and Progress
- Improved Financial Position: As of March 31, 2026, Generate Biomedicines reported $516.6 million in cash and cash equivalents, a significant increase from $221.5 million as of December 31, 2025, indicating a strong post-IPO financial position that is expected to fund operations into the first half of 2028.
- Increased R&D Expenses: Research and development expenses for Q1 2026 reached $57.8 million, up from $46.8 million in the same period of 2025, primarily driven by continued investment in the GB-0895 program, reflecting the company's strategic focus on critical therapeutic areas.
- Clinical Trial Advancements: The Phase 3 clinical trials for GB-0895 are underway for severe asthma, showing promising progress, while clinical trials for GB-4362 and GB-5267 are also advancing, which is expected to bolster the company's competitive edge in the market.
- Widening Net Loss: The net loss for Q1 2026 was $61.7 million, compared to $44.3 million in Q1 2025, primarily due to increased stock-based compensation and operational costs, highlighting the financial pressures faced by the company as it expands its business.
GENERATE BIOMEDICINES INC REPORTS $61.7 MILLION NET LOSS FOR Q1
- Financial Performance: Generate Biomedicines reported a net loss of $61.7 million for the first quarter.
- Business Focus: The company continues to prioritize advancements in its biomedicine technologies despite the financial setback.
HarbourVest Partners Acquires Stake in Generate Biomedicines
- New Investment Disclosure: HarbourVest Partners disclosed a new position in Generate Biomedicines (GENB) by acquiring 1,722,210 shares in Q1 2026, with an estimated transaction value of $21.03 million, indicating strong conviction in the company's future.
- Position Value Analysis: As of March 31, 2026, the value of Generate Biomedicines' position was $21.53 million, representing 21% of HarbourVest's reportable AUM, highlighting the significance of this investment in their portfolio.
- Financial Overview: Generate Biomedicines has a market capitalization of $2 billion, and despite a revenue decline to $7.2 million year-over-year, the company holds $516.6 million in cash and equivalents, providing a runway into the first half of 2028.
- Clinical Progress and Strategy: The lead candidate GB-0895 is advancing through Phase 3 trials, with management emphasizing progress across multiple programs, showcasing the company's potential in drug development and AI-driven discovery platforms.
HarbourVest Acquires 1.72 Million Shares of Generate Biomedicines
- Share Acquisition: HarbourVest initiated a position in Generate Biomedicines by acquiring 1,722,210 shares in Q1 2026, with an estimated transaction value of $21.03 million, indicating strong conviction in the company's potential, especially given its clinical pipeline advancements.
- Asset Growth: As of March 31, 2026, HarbourVest's position in Generate was valued at $21.53 million, reflecting a 21% increase in reportable assets under management, driven by both share purchases and favorable price movements in the market.
- Financial Position: Generate Biomedicines ended the quarter with $516.6 million in cash and equivalents, despite a revenue decline from $8.8 million to $7.2 million year-over-year, as the company ramps up investments in late-stage clinical programs, showcasing its long-term growth potential.
- Clinical Progress: The lead candidate GB-0895 is advancing through Phase 3 trials for severe asthma, while oncology candidates are expected to initiate key clinical activities later this year, highlighting the company's ongoing commitment to drug development and strategic positioning in the biotech sector.
Generate Biomedicines to Participate in Goldman Sachs Global Healthcare Conference
- Conference Participation Announcement: Generate Biomedicines (NASDAQ:GENB) has announced its participation in the Goldman Sachs Global Healthcare Conference on June 8, 2026, with a live webcast expected to enhance visibility and trust among investors.
- Innovative Platform Overview: The company focuses on the intersection of machine learning, biological engineering, and medicine, aiming to accelerate drug development through its generative platform to create superior therapeutic solutions that meet urgent patient needs.
- Pipeline Expansion: By integrating computational design with large-scale biological experimentation, the platform has successfully generated a variety of therapeutic solutions targeting health challenges that traditional methods struggle to address, showcasing significant innovation potential and market competitiveness.
- Company Background Summary: Founded in 2018, Generate Biomedicines is leading a fundamental shift from drug discovery to drug generation, committed to developing novel therapies for hard-to-drug targets, thereby advancing the progress and development of the biopharmaceutical industry.
Generate Biomedicines Reports Q1 2026 Financial Results and Clinical Progress
- Improved Financial Position: As of March 31, 2026, Generate reported cash and cash equivalents of $516.6 million, a significant increase from $221.5 million on December 31, 2025, reflecting the successful completion of its IPO which raised $369.3 million in net proceeds, thereby securing funding for future operations.
- Increased R&D Expenses: Research and development expenses for Q1 2026 reached $57.8 million, up from $46.8 million in Q1 2025, primarily driven by continued investment in the GB-0895 program, indicating a strategic focus on severe asthma treatment.
- Significant Clinical Progress: Generate is advancing its GB-0895 program into Phase 3 clinical trials for severe asthma and is conducting a Phase 1b trial for COPD, which is expected to enhance the company's competitive position in the respiratory disease market.
- Widening Net Loss: The net loss for Q1 2026 was $61.7 million, compared to $44.3 million in Q1 2025, largely due to increased stock-based compensation expenses, which may negatively impact investor confidence.
Generate Biomedicines Reports Q1 Highlights and Progress
- Improved Financial Position: As of March 31, 2026, Generate Biomedicines reported $516.6 million in cash and cash equivalents, a significant increase from $221.5 million as of December 31, 2025, indicating a strong post-IPO financial position that is expected to fund operations into the first half of 2028.
- Increased R&D Expenses: Research and development expenses for Q1 2026 reached $57.8 million, up from $46.8 million in the same period of 2025, primarily driven by continued investment in the GB-0895 program, reflecting the company's strategic focus on critical therapeutic areas.
- Clinical Trial Advancements: The Phase 3 clinical trials for GB-0895 are underway for severe asthma, showing promising progress, while clinical trials for GB-4362 and GB-5267 are also advancing, which is expected to bolster the company's competitive edge in the market.
- Widening Net Loss: The net loss for Q1 2026 was $61.7 million, compared to $44.3 million in Q1 2025, primarily due to increased stock-based compensation and operational costs, highlighting the financial pressures faced by the company as it expands its business.
GENERATE BIOMEDICINES INC REPORTS $61.7 MILLION NET LOSS FOR Q1
- Financial Performance: Generate Biomedicines reported a net loss of $61.7 million for the first quarter.
- Business Focus: The company continues to prioritize advancements in its biomedicine technologies despite the financial setback.
